TriSalus Life Sciences to Hold Q1 2024 Financial Results Call

TriSalus Life Sciences Inc., a company specializing in oncology, has announced it will host a conference call and webcast on May 15, 2024, at 9:00 a.m. ET. The purpose of this call is to discuss the financial results for the first quarter, which ended on March 31, 2024, as well as to provide a business update. A press release detailing these first-quarter results will be issued before the call. The event will be streamed live on the investor relations section of the TriSalus website. After the event concludes, a replay of the webcast will be available on the website for about 90 days. Participants who wish to join by phone will need to register through an online form, after which they will receive dial-in details via an auto-generated email containing a link to the conference phone number and a personal pin.

TriSalus Life Sciences is dedicated to transforming the treatment of liver and pancreatic tumors through its innovative drug delivery technology and immunotherapy. The company's platform features FDA-cleared devices that use a proprietary Pressure-Enabled Drug Delivery™ (PEDD™) method to enhance therapeutic delivery to tumors. The TriNav® Infusion System is designed for the hepatic arterial infusion of liver tumors, while the Pancreatic Retrograde Venous Infusion System targets pancreatic tumors. The PEDD approach is engineered to manage pressure and flow, delivering more therapeutic agents directly to the tumor and minimizing unwanted delivery to healthy tissues, which holds the potential to improve patient outcomes.

In addition to its delivery technology, TriSalus is developing an investigational immunotherapy called nelitolimod. This candidate aims to counteract the immunosuppressive environment often created by tumors, which can render current immunotherapies ineffective in the liver and pancreas. Clinical trials under the Pressure-Enabled Regional Immuno-Oncology™ (PERIO) program have generated patient data supporting the hypothesis that nelitolimod delivered via PEDD may induce positive immune effects both within the liver and systemically. The target for nelitolimod, known as TLR9, is present across various cancer types, and the mechanical barriers addressed by PEDD are also commonly found. This investigational drug, delivered through PEDD, will be studied across multiple indications to tackle immune dysfunction and overcome barriers to drug delivery in the liver and pancreas.

TriSalus collaborates with leading cancer centers across the United States and leverages its extensive expertise in immuno-oncology and innovative technology development. The company is committed to advancing treatments that improve outcomes for patients with liver and pancreatic tumors.